|
 |
| |
 |
|
|
|
|
| |
Board of Directors
|
|
 |
Alan Lewis, Ph.D. |
|
| |
President
and Chief Executive Office, Novocell, Inc.
Dr. Lewis was elected to BioMarin's board of directors
in June 2005. He currently serves as President and
Chief Executive Office of Novocell, Inc, a position
he has held since February 2006. Prior to joining
Novocell, Dr. Lewis served as President of Celgene
Signal Research, an integrated pharmaceutical company.
Previously, he was the President and Chief Executive
Officer of Signal Pharmaceuticals, Inc., where he
guided the company to its successful acquisition
by Celgene. From 1979 to 1994, Dr. Lewis held a
number of positions at Wyeth-Ayerst Research and
its predecessor Wyeth Laboratories, Inc., including
Vice President of Research at Wyeth-Ayerst. Dr.
Lewis has published over 120 full manuscripts and
has written and edited seven books and 100 abstracts.
Dr. Lewis was a Research Associate at Yale University
from 1972 to 1973. Dr. Lewis received a B.Sc. in
Physiology and Biochemistry from Southampton University,
Southampton, Hampshire, U.K. and a Ph.D. in Pharmacology
from the University of Wales, Cardiff, U.K.
|
|
| |
|
|
|
|
|
